

# UC San Diego

## UC San Diego Previously Published Works

### Title

To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials.

### Permalink

<https://escholarship.org/uc/item/0hw0p1mm>

### Journal

Journal of Virus Eradication, 9(3)

### ISSN

2055-6640

### Authors

Patel, Hursch

Dubé, Karine


### Publication Date

2023-09-01

### DOI

10.1016/j.jve.2023.100339

Peer reviewed



# To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials

Hursch Patel<sup>a,\*</sup>, Karine Dubé<sup>a,b</sup>

<sup>a</sup> University of California San Diego School of Medicine, Division of Infectious Diseases and Global Public Health (IDGPH), La Jolla, San Diego, CA, USA

<sup>b</sup> University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA

## ARTICLE INFO

### Keywords:

Broadly neutralizing antibodies  
Pre-screening  
Sensitivity  
HIV cure research

## ABSTRACT

The use of broadly neutralizing antibodies (bNAbs) as a cure-related research strategy for human immunodeficiency virus (HIV) has gained attention from the scientific community. bNAbs are specialized antibodies that target HIV-1 by binding to proteins on the surface of the virus, preventing the infection of human cells. In HIV-1 clinical studies assessing the use of bNAbs, it has been common practice to prescreen potential participants for bNAb sensitivity. However, the use of pre-screening in HIV-1 bNAb clinical trials is a topic of ongoing debate, with regard to its potential benefits and limitations. In this paper, we examine the possible benefits and limitations of pre-screening for bNAb sensitivity in HIV-1 cure-related studies, and suggest alternative methods which may be more effective or efficient at saving costs and time. Ultimately, the decision to use pre-screening in HIV-1 bNAb clinical trials should be based on a careful assessment of the potential benefits and limitations of this approach, as well as the specific needs, goals, design, and population of the study in question.

## 1. Introduction

Human immunodeficiency virus type-1 (HIV-1) is an ongoing global health issue that has claimed the lives of millions of people worldwide.<sup>1</sup> While antiretroviral treatment (ART) has significantly reduced morbidity and mortality associated with HIV-1, it does not eradicate the virus.<sup>2–4</sup> To this extent, the development of HIV-1 broadly neutralizing antibodies (bNAbs) is of growing interest to the HIV-1 cure scientific community.<sup>5</sup> bNAbs are specialized antibodies that can target HIV-1 directly by binding to proteins on the surface of the virus to prevent the infection of human cells.<sup>6</sup> Consequently, bNAbs can neutralize a wide range of HIV-1 strains, and combinations have been found to broaden antiviral coverage.<sup>6</sup> With the promising advantages bNAbs have shown in helping control HIV-1 combined with enhancements – such as increased breadth, potency, broader, extended bioavailability, novel delivery platforms, and combinations with other agents – clinical studies assessing their use as a potential treatment option are growing.<sup>6–9</sup> In these studies, it has been common practice to prescreen potential participants for bNAb sensitivity to ensure that they are appropriate trial candidates. Pre-screening involves identifying individuals who are likely to display viral sensitivity to the bNAb(s) under investigation, using a pre-defined assay, prior to trial enrollment.<sup>10</sup>

Pre-screening is an important study consideration as it has been well-documented that those individuals with resistance are less likely to respond to the bNAb intervention and achieve sustained ART-free viral control.<sup>11</sup> Such information should therefore be included in informed consent forms for any future study that forgoes pre-screening. However, there is an ongoing debate regarding the effectiveness and value of pre-screening in bNAb clinical trials, as well as the accuracy of the pre-screening methods that are currently available.

In this viewpoint paper, we examine the benefits and limitations of pre-screening in HIV-1 bNAb studies. We then outline possible avenues for future research.

## 2. Discussion

### 2.1. Pre-screening information

There are currently four main methods used in the pre-screening of HIV-1 bNAb clinical trials: the PhenoSense assay, the TZM-bl neutralization assay, Genotyping, and the Sequencing Q4 assay.

\* Corresponding author.

E-mail address: [phursch@health.ucsd.edu](mailto:phursch@health.ucsd.edu) (H. Patel).

<https://doi.org/10.1016/j.jve.2023.100339>

Received 30 April 2023; Received in revised form 3 July 2023; Accepted 17 July 2023

Available online 18 July 2023

2055-6640/© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

2.2. Arguments for prescreening for bNAb sensitivity

Many clinical trials have integrated pre-screening into their study protocols, taking HIV-1 isolates from people with HIV (PWH) and testing these samples against bNAbs to determine if these trial candidates will respond to the bNAb intervention.<sup>10,14–21</sup> Pre-screening supports the idea that trial enrollment should be limited to those most likely to benefit from the bNAb in question. This technique reduces the number of participants needed to demonstrate the initial effectiveness of a bNAb.<sup>22</sup> Consequently, one of the main reasons for pre-screening is to not only ensure that the study sample is representative of the population of interest, but also to reduce the risk of adverse events and protect individuals who may not benefit from treatment from undergoing unnecessary risks. Through prescreening, researchers can increase the validity and reliability of their results around bNAb efficacy.

Another common reason for pre-screening involves the high diversity within the HIV-1 reservoir in addition to HIV-1 high mutation rates, both of which account for viral isolates frequently becoming resistant to certain bNAbs and can be detected by bNAb assays using DNA and RNA, respectively.<sup>23–25</sup> As reviewed by Yu and colleagues, there have been many reports from both animal and clinical trials stating that bNAb treatment failure has occurred due to the rapid selection of bNAb-resistant viral variants.<sup>23</sup> Additionally, in a separate study assessing the bNAbs 3BNC117 and 10–1074, Bar-On et al. have found that only 67% and 58% of trial candidates tested showed sensitivity to 3BNC117 and 10–1074 on prescreening data from a TZM-bl assay, respectively.<sup>26</sup> Other researchers like Wilson et al. have explicitly stated that pre-screening participants for neutralization sensitivity directly increased the effectiveness of the bNAbs under investigation, emphasizing the importance of developing future methods to overcome bNAb resistance.<sup>27,28</sup>

Additionally, pre-screening can potentially reduce the overall cost and time required for studies by streamlining the recruitment process and minimizing the risk of enrolling individuals who may not be eligible or suitable for the study. However, this argument is controversial given the cost of pre-screening and other disadvantages addressed in Table 1.

2.3. Arguments for not pre-screening for bNAb sensitivity

While pre-screening has been used in several bNAb clinical trials, it is not without its limitations. One main area of concern is the quality of the assays that are available. For instance, in a study by Mendoza et al., the TZM-bl neutralization assay failed to detect pre-existing resistance that was present in 2 out of 11 individuals, a pattern evidenced by several other studies within the current literature.<sup>26,29</sup> A possible explanation

for these findings is that the viral samples collected for the pre-screening assays may not be representative of an individual’s entire and diverse HIV-1 reservoir.<sup>26,29</sup> This limitation is exacerbated by the cost, time, and labor required to complete these assays, especially in studies with large numbers of potential participants.<sup>30,31</sup>

Another limitation is the finding that pre-screening results, which may indicate bNAb sensitivity, do not always correspond with actual bNAb sensitivity.<sup>32</sup> As shown by Liu et al., bNAb trial participants were found to be highly sensitive to 3BNC117 based on pre-screening data, but did not achieve complete neutralization against HIV-1, even at high antibody concentrations, leading researchers to question the accuracy of pre-screening as a description of bNAb neutralizing sensitivity.<sup>33</sup>

Additionally, many HIV bNAb studies have been successfully conducted without the use of pre-screening.<sup>8,30,34,35</sup> For instance, Gaebler et al. did not prescreen their participants and later found that 76% of them were able to maintain virological suppression for a period of time after bNAb treatment.<sup>8</sup> In fact, Hraber et al. have retrospectively concluded that prescreening was not necessary due to the high frequency of bNAb sensitivity demonstrated in their randomly selected group which did not go through pre-screening.<sup>36</sup> This group further suggested that pre-screening could bias datasets in favor of higher levels of neutralization activity.<sup>36</sup>

Other potential limitations of pre-screening for bNAb sensitivity involve accessibility considerations, such as the exclusion of certain groups or individuals from study participation. For example, some individuals may be excluded due to pre-existing conditions or other factors that could interfere with the study, which may raise concerns about access and equity. This can be seen in individuals with non-clade B virus who may be excluded from studies testing bNAbs which are optimized for clade B virus. Additionally, pre-screening may also raise concerns about the representativeness of the study sample, as certain groups or individuals may be disproportionately excluded due to pre-screening criteria. Furthermore, it is important to consider study designs as a limitation, particularly those involving newly-infected individuals with HIV-1 for whom pre-screening would inappropriately delay bNAb treatment.

2.4. Possible avenues for future research

Outside of the assay-based methods used for bNAb pre-screening, some researchers have recommended genotypic assessments as an alternative approach. Genotypic assessments analyze the nucleotide sequences of HIV-1 to identify mutations or variations which may impact on the susceptibility to certain bNAbs.<sup>10,37</sup> This technique is more efficient and cost-effective in comparison to assay-based methods

Table 1

Comparison of the PhenoSense assay, TZM-bl neutralization assay, genotyping, and sequencing Q4 assay for pre-screening in HIV broadly neutralising antibody (bNAb) clinical trials.

Method	Description	Logistics	Advantages	Disadvantages
PhenoSense Monogram assay	Measures the response of an individual’s virus to antiretroviral therapy (ART)	Cost: High Time: several days to weeks Effort: specialized equipment and personnel training	Provides insights regarding an individual’s susceptibility to various antiretroviral therapies	High cost and time
TZM-bl Neutralization assay	Measures the neutralization capacity of antibody against various strains of HIV-1	Cost: high Time: several days Effort: specialized equipment and personnel training	Provides a functional measure of the neutralizing capacity of antibodies	High cost and time
Genotyping	Analyzes the genetic composition of HIV-1 to predict antibody sensitivity	Cost: low Time: several days Effort: computational database	Provides mutational sequencing information from the virus genetic composition	Limited by availability of sequencing datasets
Sequencing Q4 assay	Analyzes HIV-1 genetic composition at different timepoints to predict antibody sensitivity	Cost: low Time: several days Effort: computational database	Provides specific sequencing information as the virus evolves	Multiple samples required at different timepoints. Limited by availability of sequencing datasets

Table Data<sup>10,12,13</sup>

and has been used by numerous HIV-1 bNAb studies.<sup>10,38–51</sup> Of note, Gaebler et al. have found that, in comparison to neutralization assays, genotypic prediction to identify resistance was inadequate, suggesting further room for improvement.<sup>8</sup>

Another alternative to assay-based pre-screening is the use of phenotyping, which measures HIV-1 replication in the presence of different drugs.<sup>53</sup> Studies using phenotyping have been able to accurately predict bNAb resistance of HIV-1 isolates in a less time-consuming and expensive way than the assay-based pre-screens.<sup>24</sup> Furthermore, Moldt et al. have found that phenotyping was as predictive as genotyping when determining bNAb sensitivity.<sup>10</sup> However, as Zacharopoulou et al. have stated, the main issue for computational techniques such as phenotyping is the limited availability of neutralization datasets.<sup>52</sup>

A growing number of HIV-1 bNAb clinical trials are replacing pre-screening with *post-hoc* analysis.<sup>8,20,54</sup> By retrospectively examining data, researchers can save the time and money that would have otherwise been spent on pre-screening, while still having the option to identify factors associated with successful bNAb outcomes.

The field is currently in a state of equipoise regarding the use of pre-screening for HIV-1 bNAb clinical trials, questioning if pre-screening is a necessary step in study designs. Despite this many investigators using bNAbs are opting not to include pre-screening due to practical limitations – cost, time, and effort – as outlined in [Supplementary Table 1](#) which compiles data on recent bNAb studies and their use or not of pre-screening. With the aforementioned alternatives to bNAb pre-screening neutralization assays, further research is needed to formulate the best approach to enrolling participants into bNAb clinical studies.

### 3. Conclusions

The use of pre-screening in HIV-1 bNAb clinical trials is undetermined, with an ongoing debate regarding its potential benefits and limitations. On one hand, pre-screening has the potential to increase the validity and reliability of a study by ensuring that the study sample is representative of the population being studied and by reducing the potential for confounding factors or biases. On the other hand, the accuracy and reliability of the assays used for pre-screening, the cost and time required to complete these assays, and considerations related to the exclusion of certain groups or individuals from participating in such studies, represent limitations. Overall, the use of pre-screening in HIV-1 bNAb clinical trials is a complex issue that requires careful evaluation. It is important to consider alternative methods, which may be more effective or efficient in reducing costs and time. Ultimately, the decision to use pre-screening should be based on a careful assessment of the potential benefits and limitations of this approach, as well as the specific needs, goals, design, and type of study population.

### Funding

K.D. has received support from UM1AI126620 (BEAT-HIV Collaboratory; PI: Luis Montaner) co-funded by NIAID, NIMH, NINDS and NIDA).

### Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: KD serves as a consultant for Gilead Sciences, Inc.

### Data availability

Data will be made available on request.

### Acknowledgements

We would like to thank Prof. Luis Montaner and Katharine Bar who

provided early input into the reference list used for this viewpoint.

### Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.jve.2023.100339>.

### References

- World Health Organization. (n.d.). HIV. World Health Organization. Retrieved January 16, 2023, from <https://www.who.int/data/gho/data/themes/hiv-aids#:~:text=Since%20the%20beginning%20of%20the,at%20the%20end%20of%202021.>
- Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med.* 1998;338(13):853–860. <https://doi.org/10.1056/nejm199803263381301>.
- Chun TW, Davey Jr RT, Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy. *Nature.* 1999;401(6756):874–875. <https://doi.org/10.1038/44755>.
- Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science.* 1997;278(5341):1295–1300. <https://doi.org/10.1126/science.278.5341.1295>.
- Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. *Nature.* 2011;477(7365):466–470. <https://doi.org/10.1038/nature10373>.
- Caskey M. Broadly neutralizing antibodies for the treatment and prevention of HIV infection. *Curr Opin HIV AIDS.* 2020;15(1):49–55. <https://doi.org/10.1097/COH.0000000000000600>.
- Caskey M, Millard K, Turroja M, et al. *Phase I study of long-acting 3BNC117 and 10-1074 in viremic adults living with HIV.* Denver, Colorado, USA: Abstract to the Conference on Retroviruses and Opportunistic Infections (CROI); 2022. Abstract 140.
- Gaebler C, Nogueira L, Stoffel E, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. *Nature.* 2022;606(7913):368–374. <https://doi.org/10.1038/s41586-022-04597-1>.
- Research toward a cure trials. Treatment Action Group Retrieved January 16, 2023, from <https://www.treatmentactiongroup.org/cure/trials/>.
- Moldt B, Parvangada A, Martin R, et al. Evaluation of broadly neutralizing antibody sensitivity by genotyping and phenotyping for qualifying participants to HIV clinical trials. *J Acquir Immune Defic Syndr.* 2021;88(1):61–69. <https://doi.org/10.1097/QAI.0000000000002722>.
- Lynch RM, Bar KJ. Development of screening assays for use of broadly neutralizing antibodies in people with HIV. *Curr Opin HIV AIDS.* 2023;18(4):171–177. <https://doi.org/10.1097/COH.0000000000000798>. Epub 2023 May 9. PMID: 37265260.
- PhenoSense®. Monogram Biosciences (n.d.). Retrieved January 16, 2023, from <https://monogrambio.labcorp.com/resources/phenotyping/phenosense>.
- Sarzotti-Kelsoe M, Bailer RT, Turk E, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. *J Immunol Methods.* 2014;409:131–146. <https://doi.org/10.1016/j.jim.2013.11.022>. Epub 2013 Dec 1. PMID: 24291345; PMCID: PMC4040342.
- Chun TW, Murray D, Justement JS, et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. *Proc Natl Acad Sci U S A.* 2014;111(36):13151–13156. <https://doi.org/10.1073/pnas.1414148111>.
- Selzer L, VanderVeen LL, Parvangada A, et al. *Susceptibility screening to bNAbs teravimab (GS-5423) and zilvirimab (GS-2872) 580 in ART-suppressed participants.* Seattle, Washington, USA: Abstract to the Conference on Retroviruses and Opportunistic Infections (CROI); Feb 2023:19–22. Poster 580.
- Eron JJ, Little SJ, Crofoot G, et al. *Lenacapavir with bNAbs GS-5423 and GS-2872 dosed every 6 months in people with HIV.* Seattle, Washington, USA: Abstract to the Conference on Retroviruses and Opportunistic Infections (CROI); 19–22 Feb, 2023. Oral poster 193.
- Giorgi EE, Kadka P, Benko E, et al. *Distinct HIV-1 resistance profiles against bNAb in intact vs defective viral genomes.* Seattle, Washington, USA: Abstract to the Conference on Retroviruses and Opportunistic Infections (CROI); 19–22 Feb 2023. Abstract 00180.
- Moldt B, Parvangada A, Martin R, et al. Evaluation of bNAb sensitivity by genotyping and phenotyping for HIV clinical trials. *J Acquir Immune Deficiency Syndr.* 2021;88(1):61–69.
- Reeves J, Zheng Y, Olefsky M, et al. Susceptibility to anti-HIV bnAbs is concordant in pre-ART plasma and on-ART PBMC samples: ACTG NW5413. In: *Abstract to the Conference on Retroviruses and Opportunistic Infections.* 19–22nd Feb 2023. Seattle, Washington, USA. 2023.
- Zacharopoulou P, et al. Mutational landscape of 10-1074 and 3BNC117 sensitivity in a UK population with PHI. In: *Conference on Retroviruses and Opportunistic Infections (CROI).* 2023, 202319–22 Feb. 2023, Seattle, Washington, USA.
- Chun TW, Sneller MC, Seamon C, et al. Effect of infusion of broadly neutralizing antibody VRC01 on HIV plasma rebound. In: *Conference on Retroviruses and Opportunistic Infections (CROI).* 2023, 19–22nd Feb, Seattle, Washington, USA.
- Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. *Antimicrob Agents Chemother.* 2007;51(2):566–575. <https://doi.org/10.1128/AAC.00853-06>.

- 23 Yu WH, Su D, Torabi J, et al. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. *JCI Insight*. 2019;4(17), e130153. <https://doi.org/10.1172/jci.insight.130153>.
- 24 Rawi R, Mall R, Shen CH, et al. Accurate prediction for antibody resistance of clinical HIV-1 isolates. *Sci Rep*. 2019;9(1):14696. <https://doi.org/10.1038/s41598-019-50635-w>.
- 25 Tebas P, Lynn K, Azzoni L, et al. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. *AIDS*. 2023. <https://doi.org/10.1097/QAD.0000000000003575>. Epub ahead of print. PMID: 37070542.
- 26 Bar-On Y, Gruell H, Schoofs T, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. *Nat Med*. 2018;24(11):1701–1707. <https://doi.org/10.1038/s41591-018-0186-4>.
- 27 Wilson A, Shakhmour L, Ward A, et al. Characterizing the relationship between neutralization sensitivity and *env* gene diversity during ART suppression. *Front Immunol*. 2021;12:710327. <https://doi.org/10.3389/fimmu.2021.710327>.
- 28 Montaner L, Lynn K, Azzoni L, et al. Susceptibility to 3BNC117 and 10-1074 in ART-suppressed chronically infected persons. Denver, Colorado, USA: Abstract to the Conference on Retroviruses and Opportunistic Infections (CROI); 2022 Feb:12–16. Abstract 503.
- 29 Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature*. 2018;561(7724):479–484. <https://doi.org/10.1038/s41586-018-0531-2>.
- 30 Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. *N Engl J Med*. 2016;375(21):2037–2050. <https://doi.org/10.1056/NEJMoa1608243>.
- 31 Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. *Antimicrob Agents Chemother*. 2000;44(4):920–928. <https://doi.org/10.1128/AAC.44.4.920-928.2000>.
- 32 Pahus M, Gunst JD, Ramos V, et al. Profiling the sensitivity of HIV to neutralizing antibodies in vivo. In: *Abstract to the Conference on Retroviruses and Opportunistic Infections (CROI)*. 2023, 19-22nd Feb., Seattle, Washington, USA. Abstract 504.
- 33 Liu Y, Cao W, Sun M, Li T. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. *Emerg Microb Infect*. 2020;9:194–206. <https://doi.org/10.1080/22221751.2020.1713707>.
- 34 Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. *Sci Transl Med*. 2015;7(319):319ra206. <https://doi.org/10.1126/scitranslmed.aad5752>.
- 35 Sneller MC, Blazkova J, Chun TW, et al. Combination anti-HIV antibodies provide sustained virological suppression. *Nature*. 2022;606(7913):375–381. <https://doi.org/10.1038/s441586-022-04797-9>.
- 36 Hrabec P, Seaman MS, Bailer RT, et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. *AIDS*. 2014;28(2):163–169. <https://doi.org/10.1097/QAD.000000000000106>.
- 37 Kouyos RD, von Wyl V, Yerly S, et al. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. *Clin Infect Dis*. 2011;52(4):532–539. <https://doi.org/10.1093/cid/ciq164>.
- 38 Banin AN, Tuen M, Bimela JS, et al. Near full genome characterization of HIV-1 unique recombinant forms in Cameroon reveals dominant CRF02\_AG and F2 recombination patterns. *J Int AIDS Soc*. 2019;22(7), e25362. <https://doi.org/10.1002/jia2.25362>. PMID: 31353798; PMCID: PMC6661401.
- 39 Stefic K, Bouvin-Pley M, Essat A, et al. Sensitivity to broadly neutralizing antibodies of recently transmitted HIV-1 clade CRF02\_AG viruses with a focus on evolution over time, 18 *J Virol*. 2019;93(2), e01492. <https://doi.org/10.1128/JVI.01492-18>. PMID: 30404804; PMCID: PMC6321924.
- 40 Ashokkumar M, Aralaguppe SG, Tripathy SP, Hanna LE, Neogi U. Unique phenotypic characteristics of recently transmitted HIV-1 subtype C envelope glycoprotein gp120: use of CXCR6 coreceptor by transmitted founder viruses 18. *J Virol*. 2018;92(9), e00063. <https://doi.org/10.1128/JVI.00063-18>. PMID: 29491151; PMCID: PMC5899188.
- 41 Ringe RP, Ozorowski G, Yasmeen A, et al. Improving the expression and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers by targeted sequence changes 17. *J Virol*. 2017;91(12), e00264. <https://doi.org/10.1128/JVI.00264-17>. PMID: 28381572; PMCID: PMC5446630.
- 42 Makhdoomi MA, Singh D, Pananghat AN, et al. Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India. *Virology*. 2016;499:105–113. <https://doi.org/10.1016/j.virol.2016.09.011>. Epub 2016 Sep 17. PMID: 27643887.
- 43 Rademeyer C, Korber B, Seaman MS, et al. Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization. *PLoS Pathog*. 2016;12(7), e1005742. <https://doi.org/10.1371/journal.ppat.1005742>. Erratum in: *PLoS Pathog*. 2017 Sep 25;13(9):e1006641. PMID: 27434311; PMCID: PMC4951126.
- 44 O'Rourke SM, Suthent R, Phung P, et al. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01\_AE viruses. *PLoS One*. 2015;10(3), e0119608. <https://doi.org/10.1371/journal.pone.0119608>. PMID: 25793890; PMCID: PMC4368187.
- 45 Lance Hepler N, Scheffler K, Weaver S, et al. IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform. *PLoS Comput Biol*. 2014;10(9), e1003842. <https://doi.org/10.1371/journal.pcbi.1003842>. PMID: 25254639; PMCID: PMC4177671.
- 46 Utachee P, Isarangkura-na-ayuthaya P, Tokunaga K, et al. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01\_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. *Retrovirology*. 2014;11:32. <https://doi.org/10.1186/1742-4690-11-32>. PMID: 24758333; PMCID: PMC4003292.
- 47 Hoffenberg S, Powell R, Carpov A, et al. Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. *J Virol*. 2013;87(10):5372–5383. <https://doi.org/10.1128/JVI.02827-12>. Epub 2013 Mar 6. PMID: 23468492; PMCID: PMC3648150.
- 48 Guo D, Luo X, Zhao A, et al. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. *J Biol Chem*. 2012;287(51):43170–43179. <https://doi.org/10.1074/jbc.M112.399402>. Epub 2012 Oct 25. PMID: 23100255; PMCID: PMC3522310.
- 49 Schader SM, Colby-Geminario SP, Quashie PK, et al. HIV gp120 H375 is unique to HIV-1 subtype CRF01\_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. *Antimicrob Agents Chemother*. 2012;56(8):4257–4267. <https://doi.org/10.1128/AAC.00639-12>. Epub 2012 May 21. PMID: 22615295; PMCID: PMC3421599.
- 50 Moore PL, Gray ES, Sheward D, et al. CAPRISA 002 Study. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. *J Virol*. 2011 Apr;85(7):3128–3141. <https://doi.org/10.1128/JVI.02658-10>. Epub 2011 Jan 26. PMID: 21270156; PMCID: PMC3067856.
- 51 Nie J, Zhang C, Liu W, et al. Genotypic and phenotypic characterization of HIV-1 CRF01\_AE env molecular clones from infections in China. *J Acquir Immune Defic Syndr*. 2010;53(4):440–450. <https://doi.org/10.1097/QAI.0b013e3181cb8300>. PMID: 20090544.
- 52 Zacharopoulou P, Ansari MA, Frater J. A calculated risk: evaluating HIV resistance to the broadly neutralising antibodies 10-1074 and 3BNC117. *Curr Opin HIV AIDS*. 2022;17(6):352–358. <https://doi.org/10.1097/COH.0000000000000764>. PMID: 36178770; PMCID: PMC9594129.
- 53 Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. <https://academic.oup.com/cid/article/32/5/774/359877>.
- 54 Julg B, Stephenson KE, Wagh K, et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. *Nat Med*. 2022;28(6):1288–1296. <https://doi.org/10.1038/s41591-022-01815-1>. Epub 2022 May 12. PMID: 35551291; PMCID: PMC9205771.